Intellia Therapeutics Inc (NASDAQ: NTLA) is -53.10% lower on its value in year-to-date trading and has touched a low of $12.82 and a high of $34.87 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NTLA stock was last observed hovering at around $13.80 in the last trading session, with the day’s gains setting it 0.5%.
Currently trading at $14.30, the stock is -5.59% and -20.41% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.4 million and changing 3.62% at the moment leaves the stock -37.94% off its SMA200. NTLA registered -52.74% loss for a year compared to 6-month loss of -42.43%. The firm has a 50-day simple moving average (SMA 50) of $17.9671 and a 200-day simple moving average (SMA200) of $23.042974.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -9.78% gain in the last 1 month and extending the period to 3 months gives it a -39.36%, and is 2.36% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.59% over the week and 7.23% over the month.
Intellia Therapeutics Inc (NTLA) has around 526 employees, a market worth around $1.51B and $43.09M in sales. Profit margin for the company is -1212.19%. Distance from 52-week low is 11.54% and -58.99% from its 52-week high. The company has generated returns on investments over the last 12 months (-49.98%).
with sales reaching $8.9M over the same period.The EPS is expected to grow by 1.94% this year, but quarterly earnings will post 45.76% year-over-year. Quarterly sales are estimated to grow 564.50% in year-over-year returns.
Intellia Therapeutics Inc (NTLA) Top Institutional Holders
420.0 institutions hold shares in Intellia Therapeutics Inc (NTLA), with institutional investors hold 92.45% of the company’s shares. The shares outstanding are 101.85M, and float is at 100.10M with Short Float at 16.14%. Institutions hold 91.33% of the Float.
The top institutional shareholder in the company is ARK INVESTMENT MANAGEMENT LLC with over 11.6 million shares valued at $259.51 million. The investor’s holdings represent 12.1419% of the NTLA Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 9.6 million shares valued at $214.79 million to account for 10.0496 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 9.1 million shares representing 9.5287% and valued at over $203.66 million, while DEEP TRACK CAPITAL, LP holds 5.0261 of the shares totaling 4.8 million with a market value of $107.42 million.
Intellia Therapeutics Inc (NTLA) Insider Activity
The most recent transaction is an insider sale by Dube Michael P , the company’s VP, Chief Accounting Officer. SEC filings show that Dube Michael P sold 2,012 shares of the company’s common stock on Oct 02 ’24 at a price of $19.01 per share for a total of $38248.0. Following the sale, the insider now owns 47012.0 shares.
Intellia Therapeutics Inc disclosed in a document filed with the SEC on Jul 01 ’24 that Clark Eliana (EVP, Chief Technical Officer) sold a total of 405 shares of the company’s common stock. The trade occurred on Jul 01 ’24 and was made at $22.93 per share for $9287.0. Following the transaction, the insider now directly holds 71470.0 shares of the NTLA stock.
Still, SEC filings show that on Jun 17 ’24, Verwiel Frank (Director) disposed off 1,505 shares at an average price of $25.00 for $37625.0. The insider now directly holds 17,948 shares of Intellia Therapeutics Inc (NTLA).
